Parastu Kasaie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Parastu Kasaie has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- David W. Dowdy
Johns Hopkins University
9 shared publications - Anthony Todd Fojo
Department of Medicine, Division of General Internal Medicine, Johns Hopkins School of Medicine , Baltimore, Maryland
5 shared publications David W. Dowdy
Johns Hopkins Bloomberg School of Public Health
5 shared publications- Emily A. Kendall
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4 shared publications Jeff Pennington
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA
4 shared publications- Keri N. Althoff
Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA
4 shared publications
Latest Publications
- 14 October 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ American Journal of Epidemiology
The effect of hypothetical interventions to limit weight gain on incident type 2 diabetes mellitus among people with HIV initiating antiretroviral therapy in the United States, 2012-2021
Among people with human immunodeficiency virus (PWH), initiating antiretroviral therapy (ART) is associated with weight gain that might increase the risk of cardiometabolic outcomes. We estimated the effect of hypothetical interventions to restrict increases in body mass index (BMI) in the 2 years after ART initiation on the 7-year risk of incident type 2 diabetes mellitus (T2DM) among PWH in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) clinical cohorts using the parametric extended g-formula. Among 13 822 normal-weight or overweight PWH (BMI ℠18.5 and ⤠29.9 kg/m2) who initiated ART between 2012 and 2021, the 7-year risk of T2DM was 5.6% (95% confidence interval [CI], 4.8%, 6.3%). Compared to no intervention on BMI, if BMI increase during the first 2 years was capped at 5% of baseline BMI, the risk ratio (RR) for T2DM risk was 0.94 (95% CI, 0.86, 1.03); if BMI was capped at 29.9 kg/m2, the RR was 0.88 (95% CI, 0.80, 0.97); and if PWH were prevented from gaining any weight over the first 2 years, the RR was 0.81 (95% CI, 0.72, 0.92). These results provide preliminary evidence to promote studies of real weight-maintenance interventions among PWH initiating ART.
- 14 October 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ American Journal of Epidemiology
The effect of hypothetical interventions to limit weight gain on incident type 2 diabetes mellitus among people with HIV initiating antiretroviral therapy in the United States, 2012-2021
Among people with human immunodeficiency virus (PWH), initiating antiretroviral therapy (ART) is associated with weight gain that might increase the risk of cardiometabolic outcomes. We estimated the effect of hypothetical interventions to restrict increases in body mass index (BMI) in the 2 years after ART initiation on the 7-year risk of incident type 2 diabetes mellitus (T2DM) among PWH in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) clinical cohorts using the parametric extended g-formula. Among 13 822 normal-weight or overweight PWH (BMI ℠18.5 and ⤠29.9 kg/m2) who initiated ART between 2012 and 2021, the 7-year risk of T2DM was 5.6% (95% confidence interval [CI], 4.8%, 6.3%). Compared to no intervention on BMI, if BMI increase during the first 2 years was capped at 5% of baseline BMI, the risk ratio (RR) for T2DM risk was 0.94 (95% CI, 0.86, 1.03); if BMI was capped at 29.9 kg/m2, the RR was 0.88 (95% CI, 0.80, 0.97); and if PWH were prevented from gaining any weight over the first 2 years, the RR was 0.81 (95% CI, 0.72, 0.92). These results provide preliminary evidence to promote studies of real weight-maintenance interventions among PWH initiating ART.
- Open Access
- 2 October 2026
- Published byĀ ElsevierĀ inĀ SSRN Electronic Journal
Doxycycline Post-Exposure Prophylaxis Uptake in the United States: Evidence from a Large Commercial Claims Database, 2016 to 2023
Background: Following US clinical guidance recommending Doxycycline post-exposure prophylaxis (Doxy-PEP) for preventing bacterial sexually transmitted infections (STI) among eligible patients, understanding its uptake is critical to assessing its potential population-level impact.Methods: Using MerativeTM MarketScanĀ® commercial claims from Jan-2016 through Dec-2023, we used ratio-of-rates and Poisson interrupted time-series analyses to estimate expected doxycycline dispensing among men before early Doxy-PEP rollout in Oct-2022. Female enrollees served as a contemporaneous internal comparison to account for underlying trends unrelated to doxy-PEP. Excess use among men was attributed to Doxy-PEP uptake. Analyses were carried across multiple populations and geographic regions, including the national cohort, four Census regions, 38 high-syphilis-burden core-based statistical areas (CBSAs), HIV pre-exposure prophylaxis (PrEP) users, and people with HIV (PWH).Results: Nationally, Doxy-PEP uptake was estimated at 0.09 excess unique male doxycycline users per 1,000 male enrollee-months [95%Confidence interval: 0.08ā0.10], corresponding to 7.2% of all doxycycline dispensing records among men in Dec-2023. Uptake rates were highest in the West (0.36[0.33ā0.38]) and Northeast (0.27 [0.24ā0.30]) regions. Estimated uptake was higher among key populations, ranging from 6.25- 6.41 per 1,000 male enrollee-months among PrEP users, and 6.81- 9.2 among PWH. Thirteen of 38 CBSAs showed no statistically detectable increase in male doxycycline use post-Oct-2022.Conclusions: Our results demonstrate increased doxycycline dispensing among men and key populations following the Oct-2022 early Doxy-PEP rollout, consistent with growing uptake. Geographic estimates revealed persistent gaps in uptake at the local level, underscoring the need for expanded STI prevention access in areas with lower Doxy-PEP uptake.
- 2 October 2026
- Published byĀ ElsevierĀ inĀ SSRN Electronic Journal
Open AccessDoxycycline Post-Exposure Prophylaxis Uptake in the United States: Evidence from a Large Commercial Claims Database, 2016 to 2023
Background: Following US clinical guidance recommending Doxycycline post-exposure prophylaxis (Doxy-PEP) for preventing bacterial sexually transmitted infections (STI) among eligible patients, understanding its uptake is critical to assessing its potential population-level impact.Methods: Using MerativeTM MarketScanĀ® commercial claims from Jan-2016 through Dec-2023, we used ratio-of-rates and Poisson interrupted time-series analyses to estimate expected doxycycline dispensing among men before early Doxy-PEP rollout in Oct-2022. Female enrollees served as a contemporaneous internal comparison to account for underlying trends unrelated to doxy-PEP. Excess use among men was attributed to Doxy-PEP uptake. Analyses were carried across multiple populations and geographic regions, including the national cohort, four Census regions, 38 high-syphilis-burden core-based statistical areas (CBSAs), HIV pre-exposure prophylaxis (PrEP) users, and people with HIV (PWH).Results: Nationally, Doxy-PEP uptake was estimated at 0.09 excess unique male doxycycline users per 1,000 male enrollee-months [95%Confidence interval: 0.08ā0.10], corresponding to 7.2% of all doxycycline dispensing records among men in Dec-2023. Uptake rates were highest in the West (0.36[0.33ā0.38]) and Northeast (0.27 [0.24ā0.30]) regions. Estimated uptake was higher among key populations, ranging from 6.25- 6.41 per 1,000 male enrollee-months among PrEP users, and 6.81- 9.2 among PWH. Thirteen of 38 CBSAs showed no statistically detectable increase in male doxycycline use post-Oct-2022.Conclusions: Our results demonstrate increased doxycycline dispensing among men and key populations following the Oct-2022 early Doxy-PEP rollout, consistent with growing uptake. Geographic estimates revealed persistent gaps in uptake at the local level, underscoring the need for expanded STI prevention access in areas with lower Doxy-PEP uptake.
- Open Access
When Cuts Cost More: Projected Fiscal Impact of Eliminating the AIDS Drug Assistance Program in 30 US States
Background: The AIDS Drug Assistance Program (ADAP) supports antiretroviral therapy for low-income people with HIV. We assessed whether ADAP savings would offset additional HIV care costs resulting from new infections. Methods: Using the Joint HIV Epidemiologic and Economic Model calibrated to 30 US states and the District of Columbia, we compared continued 2025 ADAP coverage with elimination beginning Jan-2026. We projected excess HIV infections and care costs through 2035 under three cost-scenarios. Projected costs were limited to HIV care costs attributable to excess incident infections that would results from eliminating ADAP. The primary outcome was the Net Cost to Expenditure Ratio (NCER), defined as healthcare-system costs minus ADAP expenditure, relative to ADAP expenditure by 2035. Results: Across the modeled US jurisdictions, ADAP elimination was projected to result in a median of 143,347 additional HIV incident cases, generating $11.24 billion in HIV care costs through 2035. Compared with $6.58 billion in ADAP spending, this resulted in $4.66 billion in net additional costs (NCER=0.71). For every $1 in ADAP spending avoided, the healthcare system incurred $1.71 in downstream HIV care costs, a net increase of $0.71. This pattern was strongest in states with high baseline ADAP coverage and more rural HIV populations, many of which were Medicaid non-expansion states in the South, with substantial variation in NCER across jurisdictions (3.79 in Missouri to ā0.97 in the District of Columbia). Conclusions: Eliminating ADAP would be medically and fiscally counterproductive, increasing HIV burden and generating healthcare costs that would exceed program savings within seven years.
Open AccessWhen Cuts Cost More: Projected Fiscal Impact of Eliminating the AIDS Drug Assistance Program in 30 US States
Background: The AIDS Drug Assistance Program (ADAP) supports antiretroviral therapy for low-income people with HIV. We assessed whether ADAP savings would offset additional HIV care costs resulting from new infections. Methods: Using the Joint HIV Epidemiologic and Economic Model calibrated to 30 US states and the District of Columbia, we compared continued 2025 ADAP coverage with elimination beginning Jan-2026. We projected excess HIV infections and care costs through 2035 under three cost-scenarios. Projected costs were limited to HIV care costs attributable to excess incident infections that would results from eliminating ADAP. The primary outcome was the Net Cost to Expenditure Ratio (NCER), defined as healthcare-system costs minus ADAP expenditure, relative to ADAP expenditure by 2035. Results: Across the modeled US jurisdictions, ADAP elimination was projected to result in a median of 143,347 additional HIV incident cases, generating $11.24 billion in HIV care costs through 2035. Compared with $6.58 billion in ADAP spending, this resulted in $4.66 billion in net additional costs (NCER=0.71). For every $1 in ADAP spending avoided, the healthcare system incurred $1.71 in downstream HIV care costs, a net increase of $0.71. This pattern was strongest in states with high baseline ADAP coverage and more rural HIV populations, many of which were Medicaid non-expansion states in the South, with substantial variation in NCER across jurisdictions (3.79 in Missouri to ā0.97 in the District of Columbia). Conclusions: Eliminating ADAP would be medically and fiscally counterproductive, increasing HIV burden and generating healthcare costs that would exceed program savings within seven years.
- Open Access
- 4 February 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical Infectious Diseases
- Vol.Ā 82 Ā (4) , e746-e754
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
Background: Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods: We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under 3 scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results: If CDC funding for HIV tests were to end on 1 October 2025, we project 12 719 additional HIV infections across 18 states by 2030 (95% credible interval, 4547ā21 896)āan increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0%ā4.7%) to a 29.9 increase in Louisiana (9.4%ā59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions: Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDC's HIV testing activities in curbing the spread of HIV in the United States.
- 4 February 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical Infectious Diseases
- Vol.Ā 82 Ā (4) , e746-e754
Open AccessThe Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
Background: Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods: We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under 3 scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results: If CDC funding for HIV tests were to end on 1 October 2025, we project 12 719 additional HIV infections across 18 states by 2030 (95% credible interval, 4547ā21 896)āan increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0%ā4.7%) to a 29.9 increase in Louisiana (9.4%ā59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions: Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDC's HIV testing activities in curbing the spread of HIV in the United States.
- Open Access
- 30 January 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ The Journal of Infectious Diseases
- Vol.Ā 233 Ā (4) , e990-e998
Modeling the Impact of Case Finding for Tuberculosis: The Role of Infection Dynamics
Background: Many individuals previously infected with Mycobacterium tuberculosis (Mtb) may clear their infections or experience substantially reduced progression risks over time. Such dynamics suggest that recent transmission is more important in driving TB incidence in high-burden settings than previously estimated; thus, the impact of interventions to reduce transmission (eg, community-based active case finding) may also be greater than previously thought. Methods: We constructed 2 models of Mtb transmission that differed only in the inclusion of a clearance mechanism. We calibrated these models independently to the same set of epidemiological data representative of a high-TB-burden setting (India) and used the calibrated models to project the impact of illustrative biennial active case-finding campaigns (75% coverage; 65% sensitivity). Results: The estimated annual risk of Mtb infection and prevalence of recent infection were substantially higher in the model with Mtb clearance, despite being fit to the same data. The clearance model projected a greater impact of case finding on the incidence of TB disease: 45% [95% uncertainty interval 28%ā57%] reduction compared to no intervention after 10 years versus 11% [6%ā18%] in the model without clearance. Conclusions: Models that allow for Mtb clearance are evidence-supported and project greater impact from active case finding than models that do not include these dynamics.
- 30 January 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ The Journal of Infectious Diseases
- Vol.Ā 233 Ā (4) , e990-e998
Open AccessModeling the Impact of Case Finding for Tuberculosis: The Role of Infection Dynamics
Background: Many individuals previously infected with Mycobacterium tuberculosis (Mtb) may clear their infections or experience substantially reduced progression risks over time. Such dynamics suggest that recent transmission is more important in driving TB incidence in high-burden settings than previously estimated; thus, the impact of interventions to reduce transmission (eg, community-based active case finding) may also be greater than previously thought. Methods: We constructed 2 models of Mtb transmission that differed only in the inclusion of a clearance mechanism. We calibrated these models independently to the same set of epidemiological data representative of a high-TB-burden setting (India) and used the calibrated models to project the impact of illustrative biennial active case-finding campaigns (75% coverage; 65% sensitivity). Results: The estimated annual risk of Mtb infection and prevalence of recent infection were substantially higher in the model with Mtb clearance, despite being fit to the same data. The clearance model projected a greater impact of case finding on the incidence of TB disease: 45% [95% uncertainty interval 28%ā57%] reduction compared to no intervention after 10 years versus 11% [6%ā18%] in the model without clearance. Conclusions: Models that allow for Mtb clearance are evidence-supported and project greater impact from active case finding than models that do not include these dynamics.
- Open Access
Impact of an Early Body Mass Index Maintenance Intervention at ART initiation on Diabetes Risk: Insights from a Simulation Study
Background Weight gain after antiretroviral therapy (ART) initiation is linked to increased risk of developing type 2 diabetes mellitus among people with HIV (PWH). This study examines the potential impact of a hypothetical body mass index (BMI) maintenance intervention after ART initiation on reducing diabetes risk among PWH in the United States (US). Methods Using an agent-based simulation of comorbidities in PWH initiating ART in the US, we simulated a hypothetical two-year intervention, where BMI remained stable for individuals who would otherwise gain BMI. Individuals starting ART between 2013ā2017 with a normal or overweight BMI and no prior diabetes diagnosis were eligible to participate. Participants were followed under an intervention scenario and a control scenario with no intervention. Diabetes risk was calculated as new diagnoses per 1,000 person-years over seven years after ART initiation. Results The model forecasted that 171,000 PWH would initiate ART between 2013ā2017, with 73% meeting eligibility criteria. Without intervention, 66% were expected to gain BMI, and 12% would become obese. The forecasted diabetes risk was 10.7 per 1,000 person-years, with approximately 9,500 new diagnoses over seven years after ART initiation. Under the hypothetical intervention, diabetes risk was reduced by 19% and a median of 1,800 diagnoses were averted. Subgroup analyses showed the largest risk reductions among women who inject drugs and Hispanic heterosexual men. Conclusion Preventing BMI increases in ART initiators could significantly reduce diabetes risk and improve health outcomes among PWH. Tailored weight maintenance strategies are needed to address diverse subgroup needs.
Open AccessImpact of an Early Body Mass Index Maintenance Intervention at ART initiation on Diabetes Risk: Insights from a Simulation Study
Background Weight gain after antiretroviral therapy (ART) initiation is linked to increased risk of developing type 2 diabetes mellitus among people with HIV (PWH). This study examines the potential impact of a hypothetical body mass index (BMI) maintenance intervention after ART initiation on reducing diabetes risk among PWH in the United States (US). Methods Using an agent-based simulation of comorbidities in PWH initiating ART in the US, we simulated a hypothetical two-year intervention, where BMI remained stable for individuals who would otherwise gain BMI. Individuals starting ART between 2013ā2017 with a normal or overweight BMI and no prior diabetes diagnosis were eligible to participate. Participants were followed under an intervention scenario and a control scenario with no intervention. Diabetes risk was calculated as new diagnoses per 1,000 person-years over seven years after ART initiation. Results The model forecasted that 171,000 PWH would initiate ART between 2013ā2017, with 73% meeting eligibility criteria. Without intervention, 66% were expected to gain BMI, and 12% would become obese. The forecasted diabetes risk was 10.7 per 1,000 person-years, with approximately 9,500 new diagnoses over seven years after ART initiation. Under the hypothetical intervention, diabetes risk was reduced by 19% and a median of 1,800 diagnoses were averted. Subgroup analyses showed the largest risk reductions among women who inject drugs and Hispanic heterosexual men. Conclusion Preventing BMI increases in ART initiators could significantly reduce diabetes risk and improve health outcomes among PWH. Tailored weight maintenance strategies are needed to address diverse subgroup needs.
- 1 November 2025
- Published byĀ American College of PhysiciansĀ inĀ Annals of Internal Medicine
- Vol.Ā 178 Ā (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- 1 November 2025
- Published byĀ American College of PhysiciansĀ inĀ Annals of Internal Medicine
- Vol.Ā 178 Ā (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- Open Access
The Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 18 States
Background Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under three scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results If CDC funding for HIV tests were to end on October 1, 2025, we project 12,719 additional HIV infections across 18 states by 2030 (95% Credible Interval 4,547 to 21,896) ā an increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0 to 4.7%) to a 29.9 increase in Louisiana (9.4 to 59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDCās HIV testing activities in curbing the spread of HIV in the US. Summary A complete cessation of CDC-funded HIV testing could cause a 10% increase in infections by 2030 across 18 U.S. states, with this impact disproportionately affecting rural states. Mobilizing access to alternative HIV testing would be critical to mitigating this impact.
Open AccessThe Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 18 States
Background Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under three scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results If CDC funding for HIV tests were to end on October 1, 2025, we project 12,719 additional HIV infections across 18 states by 2030 (95% Credible Interval 4,547 to 21,896) ā an increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0 to 4.7%) to a 29.9 increase in Louisiana (9.4 to 59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDCās HIV testing activities in curbing the spread of HIV in the US. Summary A complete cessation of CDC-funded HIV testing could cause a 10% increase in infections by 2030 across 18 U.S. states, with this impact disproportionately affecting rural states. Mobilizing access to alternative HIV testing would be critical to mitigating this impact.
- Open Access
Modeling the impact of case finding for tuberculosis: The role of infection dynamics
Background: Our understanding of Mycobacterium tuberculosis (Mtb) natural history and infection dynamics is evolving, including recognition that many individuals previously infected with Mtb may clear their infections or experience substantially reduced progression risks with time since infection. Such dynamics suggest that recent transmission is more important in driving TB incidence in high-burden settings than previously estimated; thus, the impact of interventions to reduce transmission (e.g., community-based active case-finding) may also be greater than previously thought. Methods: We constructed two models of Mtb transmission that differed only in that one model included a clearance mechanism while the other did not. We then calibrated these models independently to the same set of epidemiological data representative of a high-TB-burden setting (India). Finally, we used the calibrated models to project the impact of illustrative biennial active case-finding campaigns (achieving 75% population coverage with 65% screening sensitivity). Results: The model that included a clearance mechanism projected a greater impact of case-finding on the incidence of TB disease: 45% [95% uncertainty interval 28-57%] reduction versus no intervention after 10 years, versus 11% [6-18%] in the model without a clearance mechanism. The estimated annual risk of Mtb infection and prevalence of recent infection were both substantially higher in the model that allowed for Mtb clearance, despite being fit to the same data. Conclusions: Models that allow for Mtb clearance are supported by biological and epidemiological evidence and project greater impact from active case-finding than models that do not include these dynamics.
Open AccessModeling the impact of case finding for tuberculosis: The role of infection dynamics
Background: Our understanding of Mycobacterium tuberculosis (Mtb) natural history and infection dynamics is evolving, including recognition that many individuals previously infected with Mtb may clear their infections or experience substantially reduced progression risks with time since infection. Such dynamics suggest that recent transmission is more important in driving TB incidence in high-burden settings than previously estimated; thus, the impact of interventions to reduce transmission (e.g., community-based active case-finding) may also be greater than previously thought. Methods: We constructed two models of Mtb transmission that differed only in that one model included a clearance mechanism while the other did not. We then calibrated these models independently to the same set of epidemiological data representative of a high-TB-burden setting (India). Finally, we used the calibrated models to project the impact of illustrative biennial active case-finding campaigns (achieving 75% population coverage with 65% screening sensitivity). Results: The model that included a clearance mechanism projected a greater impact of case-finding on the incidence of TB disease: 45% [95% uncertainty interval 28-57%] reduction versus no intervention after 10 years, versus 11% [6-18%] in the model without a clearance mechanism. The estimated annual risk of Mtb infection and prevalence of recent infection were both substantially higher in the model that allowed for Mtb clearance, despite being fit to the same data. Conclusions: Models that allow for Mtb clearance are supported by biological and epidemiological evidence and project greater impact from active case-finding than models that do not include these dynamics.
- 6 March 2024
- Published byĀ SAGE PublicationsĀ inĀ Medical Decision Making
- Vol.Ā 44 Ā (3) , 307-319
A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing
Background: Laboratory networks provide services through onsite testing or through specimen transport to higher-tier laboratories. This decision is based on the interplay of testing characteristics, treatment characteristics, and epidemiological characteristics. Objectives: Our objective was to develop a generalizable model using the threshold approach to medical decision making to inform test placement decisions. Methods: We developed a decision model to compare the incremental utility of onsite versus send-out testing for clinical purposes. We then performed Monte Carlo simulations to identify the settings under which each strategy would be preferred. Tuberculosis was modeled as an exemplar. Results: The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. When the sensitivity decrements of onsite testing were minimal, onsite testing tended to be preferred when send-out delays reduced clinical utility by >20%. By contrast, when onsite testing incurred large reductions in sensitivity, onsite testing tended to be preferred when utility lost due to delays was >50%. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs. Conclusions: Decision makers can select onsite versus send-out testing in an evidence-based fashion using estimates of the percentage of clinical utility lost due to send-out delays and the relative accuracy of onsite versus send-out testing. This model is designed to be generalizable to a wide variety of use cases. Highlights: The design of laboratory networks, including the decision to place diagnostic instruments at the point-of-care or at higher tiers as accessed through specimen transport, can be informed using the threshold approach to medical decision making. The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. The threshold approach to medical decision making can be used to compare point-of-care testing accuracy decrements with the lost utility of treatment due to send-out testing delays. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs.
- 6 March 2024
- Published byĀ SAGE PublicationsĀ inĀ Medical Decision Making
- Vol.Ā 44 Ā (3) , 307-319
A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing
Background: Laboratory networks provide services through onsite testing or through specimen transport to higher-tier laboratories. This decision is based on the interplay of testing characteristics, treatment characteristics, and epidemiological characteristics. Objectives: Our objective was to develop a generalizable model using the threshold approach to medical decision making to inform test placement decisions. Methods: We developed a decision model to compare the incremental utility of onsite versus send-out testing for clinical purposes. We then performed Monte Carlo simulations to identify the settings under which each strategy would be preferred. Tuberculosis was modeled as an exemplar. Results: The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. When the sensitivity decrements of onsite testing were minimal, onsite testing tended to be preferred when send-out delays reduced clinical utility by >20%. By contrast, when onsite testing incurred large reductions in sensitivity, onsite testing tended to be preferred when utility lost due to delays was >50%. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs. Conclusions: Decision makers can select onsite versus send-out testing in an evidence-based fashion using estimates of the percentage of clinical utility lost due to send-out delays and the relative accuracy of onsite versus send-out testing. This model is designed to be generalizable to a wide variety of use cases. Highlights: The design of laboratory networks, including the decision to place diagnostic instruments at the point-of-care or at higher tiers as accessed through specimen transport, can be informed using the threshold approach to medical decision making. The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. The threshold approach to medical decision making can be used to compare point-of-care testing accuracy decrements with the lost utility of treatment due to send-out testing delays. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs.